6 news items
Verve Therapeutics Announces Leadership Update
VERV
31 May 24
of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding timing
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
VERV
8 May 24
release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
VERV
7 May 24
contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws
VERV
19 Apr 24
("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
VERV
2 Apr 24
) -- The Schall Law Firm, a national shareholder rights litigation firm, announces
141i7yiix1h490imw0t3ll9tq9g1royn1mb41xa33eqgh pwom2nq
VERV
2 Apr 24
StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act
- Prev
- 1
- Next